患者の医療記録を対象とした新たな分析によると、2型糖尿病の成人がGLP-1受容体作動薬を使用した場合、他の一般的な糖尿病治療薬を使用した場合と比較して、脱毛症の発症率が高いことが示された。
2026年7月22日に「The BMJ」誌に掲載されたこの研究では、2019年1月から2024年9月までに治療を受けたペンシルベニア大学医療システム（Penn Medicine）の患者の電子カルテが分析された。
年齢、性別、ボディマス指数（BMI）などの要因を調整した結果、GLP-1受容体作動薬の利用者は、SGLT-2阻害薬の利用者と比較して脱毛症のリスクが37％、DPP-4阻害薬の利用者と比較して68％高いことが示された。
リスクの増加が見られたのは、髪が再生する可能性のある非瘢痕性脱毛症に限られていた。絶対的な発症率は、1,000人年あたり約6～7件と低い水準にとどまっている。
研究者らは、これらの薬剤に伴う急激な体重減少が、栄養不足やホルモンバランスの変化を通じて影響を及ぼしている可能性があると指摘したが、因果関係については本研究では特定できなかった。
AIによるレポート AIによって生成された画像 事実確認済み
A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.
A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.
AIによるレポート 事実確認済み
A year-long observational study in Japan suggests that people with type 2 diabetes who tend to overeat in response to tempting food cues such as sight and smell may see greater weight loss—and possibly better blood-sugar improvement—after starting GLP-1 receptor agonists, while those with primarily emotional eating patterns show less consistent links to long-term outcomes.
Researchers say genetic variants in the PAM gene may help explain why some people with Type 2 diabetes get less blood-sugar benefit from GLP-1 receptor agonist drugs such as Ozempic, a phenomenon they describe as “GLP-1 resistance.”
AIによるレポート 事実確認済み
A study from Rutgers University reports that adults currently using GLP-1 receptor agonist medications—including semaglutide brands Ozempic and Wegovy—showed a substantially weaker association between impulsivity and self-reported violent behavior than former users. The research, published June 17, 2026 in the journal Criminology, was based on a 2025 U.S. survey and does not establish cause and effect.
Stanford Medicine researchers say they have identified a naturally occurring 12–amino-acid peptide, BRP, that suppressed appetite and reduced body weight in animal studies. The team used a computational tool dubbed “Peptide Predictor” to identify the molecule, and reported that BRP produced anti-obesity effects in mice and minipigs without signs of nausea- or aversion-like responses seen with some GLP-1–based drugs.